Still to be defined, however, was the mechanistic rationale for a therapeutic intervention that could prevent the activation of NFκB and AP-1 and thereby restore antiestrogen sensitivity to such high-risk ER-positive breast cancers. Here, NFKB1 is linked to breast carcinoma.